This HTML5 document contains 103 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00935/identifier/wikipedia/
n20http://linked.opendata.cz/resource/AHFS/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00935/identifier/pharmgkb/
n25http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n22http://linked.opendata.cz/resource/drugbank/company/
n18http://linked.opendata.cz/resource/drugbank/dosage/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00935/identifier/bindingdb/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00935/identifier/kegg-compound/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00935/identifier/pubchem-compound/
n11http://bio2rdf.org/drugbank:
n30http://linked.opendata.cz/resource/drugbank/drug/DB00935/identifier/pubchem-substance/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00935/identifier/iuphar/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00935/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB00935/identifier/guide-to-pharmacology/
n23http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00935/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n24http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n28http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00935/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n4http://linked.opendata.cz/resource/atc/
n3http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00935
rdf:type
n5:Drug
n5:description
A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251)
n5:dosage
n18:271B6415-363D-11E5-9242-09173F13E4C5 n18:271B6416-363D-11E5-9242-09173F13E4C5 n18:271B6417-363D-11E5-9242-09173F13E4C5 n18:271B6418-363D-11E5-9242-09173F13E4C5
n5:group
approved
n5:indication
For treatment of nasal congestion and redness associated with minor irritations of the eye
n5:manufacturer
n22:271B6400-363D-11E5-9242-09173F13E4C5 n22:271B6401-363D-11E5-9242-09173F13E4C5
owl:sameAs
n11:DB00935 n23:DB00935
dcterms:title
Oxymetazoline
adms:identifier
n8:PA164748840 n9:Oxymetazoline n12:124 n13:4475 n14:DB00935 n15:42002-204-05 n16:124 n17:C07363 n19:50027075 n29:4636 n30:46505622
n5:mechanismOfAction
Oxymetazoline is a direct acting sympathomimetic amine, which acts on alpha-adrenergic receptors in the arterioles of the conjunctiva and nasal mucosa. It produces vasoconstriction, resulting in decreased conjunctival congestion in ophthalmic. In nasal it produces constriction, resulting in decreased blood flow and decreased nasal congestion.
n5:packager
n22:271B63FE-363D-11E5-9242-09173F13E4C5 n22:271B63FF-363D-11E5-9242-09173F13E4C5 n22:271B63FC-363D-11E5-9242-09173F13E4C5 n22:271B63FD-363D-11E5-9242-09173F13E4C5 n22:271B63FA-363D-11E5-9242-09173F13E4C5 n22:271B63FB-363D-11E5-9242-09173F13E4C5 n22:271B63F8-363D-11E5-9242-09173F13E4C5 n22:271B63F9-363D-11E5-9242-09173F13E4C5 n22:271B63F6-363D-11E5-9242-09173F13E4C5 n22:271B63F7-363D-11E5-9242-09173F13E4C5 n22:271B63F4-363D-11E5-9242-09173F13E4C5 n22:271B63F5-363D-11E5-9242-09173F13E4C5
n5:synonym
Oxymetazolinum Oxymethazoline 6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol Oxymetozoline 2-(4-Tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline 6-Tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol Oximetazolinum Oxymetazolina 3-[(4,5-dihydro-1H-Imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol
n3:hasAHFSCode
n20:52-32-00
n5:salt
n24:hasConcept
n25:M0015681
foaf:page
n28:oxymetazoline-solution.html
n5:IUPAC-Name
n6:271B641D-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B6423-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B6422-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B641F-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B6420-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B6421-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B641B-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B641C-363D-11E5-9242-09173F13E4C5 n6:271B6419-363D-11E5-9242-09173F13E4C5 n6:271B6434-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B641A-363D-11E5-9242-09173F13E4C5
n3:hasATCCode
n4:R01AA05 n4:S01GA04 n4:R01AB07
n5:H-Bond-Acceptor-Count
n6:271B6429-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B642A-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B6424-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B6425-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B6427-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B6426-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B6428-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
1491-59-4
n5:category
n5:containedIn
n21:271B640A-363D-11E5-9242-09173F13E4C5 n21:271B640B-363D-11E5-9242-09173F13E4C5 n21:271B6408-363D-11E5-9242-09173F13E4C5 n21:271B6409-363D-11E5-9242-09173F13E4C5 n21:271B6406-363D-11E5-9242-09173F13E4C5 n21:271B6407-363D-11E5-9242-09173F13E4C5 n21:271B6404-363D-11E5-9242-09173F13E4C5 n21:271B6405-363D-11E5-9242-09173F13E4C5 n21:271B6412-363D-11E5-9242-09173F13E4C5 n21:271B6413-363D-11E5-9242-09173F13E4C5 n21:271B6410-363D-11E5-9242-09173F13E4C5 n21:271B6411-363D-11E5-9242-09173F13E4C5 n21:271B640E-363D-11E5-9242-09173F13E4C5 n21:271B640F-363D-11E5-9242-09173F13E4C5 n21:271B640C-363D-11E5-9242-09173F13E4C5 n21:271B640D-363D-11E5-9242-09173F13E4C5 n21:271B6402-363D-11E5-9242-09173F13E4C5 n21:271B6403-363D-11E5-9242-09173F13E4C5 n21:271B6414-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B642F-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B6431-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B6432-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B6433-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B642E-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B642D-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B6430-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B641E-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B642B-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B642C-363D-11E5-9242-09173F13E4C5